The stock is trading at $43.25 quite a bit lower than the 50 day moving average of $52.72 and impressively lower than the 200 day moving average of $55.05. The 50 day moving average moved down $-9.47 and the 200 day average moved down $-11.80. Cambrex Corporation shares had a trading volume of 692K on Tuesday. Shares saw a steep increase in trading volume of 99.20% over the normal average daily volume.
Short traders are more bearish on shares of Cambrex Corporation recently if you evaluate the rise in short interest. The company realized a rise in short interest of 5.76% between September 29, 2017 and October 13, 2017. Short interest grew 162,195 over that period. The days to cover decreased to 10.0 and the percentage of shorted shares is 0.09% as of October 13.
The following firms have recently changed their position in CBM. Aperio Group, LLC divested its investment by shedding 1,696 shares a decrease of 16.1%. Aperio Group, LLC now controls 8,832 shares worth $486,000. The total value of its holdings decreased 22.7%. As of the end of the quarter Parkside Financial Bank & Trust had acquired a total of 312 shares growing its position 3,900.0%. The value of the company’s investment in Cambrex Corporation went from $0 to $18,000 a change of inf% for the reporting period.
As of quarter end Third Avenue Management LLC had sold 5,800 shares trimming its stake by 8.4%. The value in dollars decreased from $4,116,000 to $3,470,000 a change of $646,000 quarter over quarter. As of quarter end Nationwide Fund Advisors had disposed of a total of 130,168 shares trimming its holdings by 73.1%. The value of the total investment in Cambrex Corporation decreased from $10,636,000 to $2,632,000 decreasing 75.3% quarter to quarter.
The most current P/E ratio is 15.76 and the market cap of the company is 1.42B. As of the latest earnings report the EPS was $2.74 and is estimated to be $3.08 for the current year with 32,729,000 shares presently outstanding. Analysts expect next quarter’s EPS will be $1.19 and the next full year EPS is projected to be $3.13.
Cambrex Corporation (Cambrex), launched on October 11, 1983, is a life sciences company. The Company provides products and services for the development and commercialization of generic therapeutics. Cambrex operates through four segments, which are manufacturing facilities that have been aggregated as one reportable segment. Its manufacturing facilities are owned by the subsidiaries, including Cambrex Charles City, Inc., Cambrex Karlskoga AB and Cambrex Profarmaco Milano S.r.l. The Business’s products consist of active pharmaceutical ingredients (APIs) and pharmaceutical intermediates. Its products also include other fine chemicals. The Business’s business consists of the custom development and manufacture of pharmaceutical ingredients derived from organic chemistry. The Company delivers services, including custom organic synthesis and process development; current good manufacturing practices (cGMP) manufacturing of API and intermediates from grams to hundreds of kilograms; cGMP analytical services; controlled substance research and development (R&D) and manufacture, Schedule II-V, and contract research. Cambrex is a supplier of over 90 generic APIs..